Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01602315
Title A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult
Covered Countries USA | NLD | FRA | CAN | AUS

Facility Status City State Zip Country Details
Novartis Investigative Site Sacramento California 95817 United States Details
Novartis Investigative Site San Francisco California 94101 United States Details
Novartis Investigative Site Aurora Colorado 80045 United States Details
Novartis Investigative Site Jacksonville Florida 32224 United States Details
Novartis Investigative Site Orlando Florida 32806 United States Details
Novartis Investigative Site Atlanta Georgia 30322 United States Details
Novartis Investigative Site Boston Massachusetts 02114 United States Details
Novartis Investigative Site Saint Louis Missouri 63110 United States Details
Novartis Investigative Site New York New York 10017 United States Details
Novartis Investigative Site New York New York 10029 United States Details
Novartis Investigative Site Philadelphia Pennsylvania 19104 United States Details
Novartis Investigative Site Charleston South Carolina 29425 United States Details
Novartis Investigative Site Nashville Tennessee 37232 United States Details
Novartis Investigative Site Houston Texas 77030 United States Details
Novartis Investigative Site Melbourne Victoria 3000 Australia Details
Novartis Investigative Site Murdoch Western Australia 6150 Australia Details
Novartis Investigative Site Toronto Ontario M5G 2M9 Canada Details
Novartis Investigative Site Lyon Cedex 69373 France Details
Novartis Investigative Site Toulouse Cedex 9 31059 France Details
Novartis Investigative Site Shatin, New Territories Hong Kong Details
Novartis Investigative Site Seoul Korea 03080 Korea, Republic of Details
Novartis Investigative Site Seoul Korea 06351 Korea, Republic of Details
Novartis Investigative Site Seoul 03722 Korea, Republic of Details
Novartis Investigative Site Maastricht 5800 Netherlands Details
Novartis Investigative Site Nijmegen 6500 HB Netherlands Details
Novartis Investigative Site Singapore 169610 Singapore Details
Novartis Investigative Site Tainan Taiwan ROC 70421 Taiwan Details
Novartis Investigative Site Kuei-Shan Chiang Taoyuan/ Taiwan ROC 33305 Taiwan Details
Novartis Investigative Site Taipei 10048 Taiwan Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field